Extended anticoagulation in venous thromboembolism disease. In favour

Area of Science:

• Cardiology
• Hematology
• Internal Medicine

Background:

• Venous thromboembolism (VTE) poses a lifelong risk of recurrence after the initial event.
• Discontinuation of anticoagulation therapy leaves patients susceptible to new thrombotic events indefinitely.
• Current guidelines lack specificity regarding anticoagulation duration for first unprovoked VTE.

Purpose of the Study:

• To review the evidence supporting extended anticoagulation for patients with venous thromboembolism.
• To discuss current therapeutic options for managing VTE recurrence risk.
• To inform clinical decision-making for anticoagulation duration after a first unprovoked VTE episode.

Main Methods:

• Literature review of studies on VTE recurrence.
• Analysis of clinical practice guidelines for VTE treatment duration.
• Evaluation of risk-benefit data for extended anticoagulation therapy.

Main Results:

• Anticoagulation is effective in preventing recurrence while administered.
• The risk of thrombotic events persists indefinitely after anticoagulation cessation.
• Individualized risk-benefit assessment is crucial for treatment decisions in first unprovoked VTE.

Conclusions:

• Venous thromboembolism management requires careful consideration of long-term recurrence risk.
• Extended anticoagulation is a viable option for selected patients with first unprovoked VTE.
• Personalized treatment strategies are essential for optimizing VTE patient outcomes.